Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 11,893 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 11,893 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $19.89 per share, with a total value of $236,551.77. Following the purchase, the insider directly owned 1,005,732 shares of the company’s stock, valued at $20,004,009.48. This trade represents a 1.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III acquired 18,052 shares of Surrozen stock. The stock was bought at an average price of $19.60 per share, with a total value of $353,819.20.
• On Friday, January 16th, Group Gp Lp Column III bought 2,562 shares of Surrozen stock. The stock was bought at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Wednesday, January 14th, Group Gp Lp Column III bought 5,523 shares of Surrozen stock. The shares were bought at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III purchased 12,470 shares of Surrozen stock. The shares were bought at an average price of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The shares were purchased at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

Shares of NASDAQ:SRZN opened at $17.98 on Wednesday. The firm has a market capitalization of $154.09 million, a P/E ratio of -0.80 and a beta of 0.58. The stock has a 50 day moving average price of $18.98 and a 200-day moving average price of $14.13. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, equities analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Surrozen News Roundup

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Wall Street Analyst Weigh In

Several research firms recently commented on SRZN. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Institutional Trading of Surrozen

Several institutional investors have recently added to or reduced their stakes in the business. Braidwell LP purchased a new position in shares of Surrozen in the second quarter worth $1,252,000. Stempoint Capital LP increased its holdings in Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after buying an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC raised its position in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after buying an additional 20,247 shares during the last quarter. Vanguard Group Inc. lifted its stake in Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after acquiring an additional 47,468 shares during the period. Finally, Acuta Capital Partners LLC lifted its stake in Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares during the period. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.